Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?

Intellia Therapeutics (NASDAQ: NTLA)
$10.13 ▲ +4.11%
As of Jan 7, 2026 · 4:15 PM ET

🎯 FunStock Index™: 8.2 / 10
Ultra-high risk, ultra-high reward. Binary outcomes. Strong insider conviction — but nerves required.

🧬 Quick Context

This article is an update to our earlier deep dive on NTLA. Same company. Same revolutionary CRISPR promise. Very different market mood.

Short sellers are circling. Insiders (at least some) are buying. Regulators are watching.
Welcome to biotech — where even your nerves are on trial.

🔴 Why Is Short Interest So High? (≈36% of the Float)

Let’s start with the bear case — because ignoring it is how portfolios get humbled.

🚨 1) Safety Event + FDA Clinical Hold

In October 2025, a patient in Intellia’s late-stage ATTR trial (nex-z) died following severe liver enzyme elevations.

• FDA response: clinical hold

• Market response: panic

• Stock response: down ~55% in three months

This is the headline risk shorts love.

🧪 2) Platform Contagion Fear

Short sellers aren’t just betting against one drug — they’re betting against the CRISPR in-vivo platform itself.

• Same lipid nanoparticle delivery

• Same liver targeting

• Fear: “If it failed once, it fails everywhere”

Whether that fear is justified is… the entire investment debate.

💸 3) Cash Burn + Dilution Anxiety

No approved product yet.
Cash burn ≈ $95M/quarter.
Biotech reflex: short now, wait for dilution later.

📉 4) Valuation Still “Too High” (According to Bears)

Even after the collapse, some shorts argue NTLA is still overpriced for a binary Phase 3 story.

🧯 The Setup: Why This Could Explode Either Way

📌 Translation:
Bad news → gravity
Good news → short squeeze chaos

🧪 The Catalyst That Matters: Phase 3 HAELO (Mid-2026)

This is the make-or-break moment.

• Indication: Hereditary Angioedema (HAE)

• Drug: lonvo-z

• Phase 1 data: ~98% reduction in attacks

• Topline Phase 3: expected H1 2026

🐂 Bull Case

Clean safety + strong efficacy → platform validated → shorts scramble.

🐻 Bear Case

Any liver signal → “platform risk” confirmed → shorts feel vindicated.

Binary. Brutal. Beautiful (if you like volatility).

💰 The Counter-Signal: Insiders Buying Millions

This is where the story gets interesting.

🟢 Recent Insider Purchases (Open Market)

• Fred E. Cohen (Director)
  +150,000 shares @ $9.35 → $1.40M

• William J. Chase (Director)
  +100,000 shares @ ~$10.03 → ~$1.0M

📌 Total insider buys in weeks: ~$2.4M

This is not symbolic. This is skin-in-the-game money.

⚠️ But Wait — Executives Are Selling Too

Yes. And we need to be honest about it.

Several executives (including the CEO) sold shares around ~$9.21 — mostly small percentages of much larger holdings, often tied to compensation or diversification.

📌 Key nuance:

• Directors (not paid like executives) are buying aggressively

• Executives still own far more shares than they sold

This mix doesn’t scream “all clear” — but it also doesn’t scream “run.”

It screams: complex reality.

🧠 Historical Precedent: The Alnylam (ALNY) Parallel (Used Carefully)

The case of Alnylam Pharmaceuticals may provide insight and perspective. Alnylam pioneered RNA interference (RNAi), a field that faced similar safety skepticism to CRISPR today.

• The Setback (2016): In October 2016, Alnylam’s lead drug, revusiran, was scrapped after an "imbalance of deaths" (18 deaths in the drug arm vs. placebo) in their Phase III trial. The stock crashed nearly 50% overnight, eventually trading at deep discounts as the market questioned their entire delivery platform.

• The Recovery: Alnylam didn't give up on the platform; they pivoted to a more refined delivery system (GalNAc). They eventually gained multiple FDA approvals (Onpattro, Givlaari, Amvuttra).

• The Result: Investors who bought the "broken" story in the low double-digits saw the stock climb to over $280 (and peaking even higher; it's now trading above $400) as the platform was validated.

Intellia’s "Alnylam Moment": Intellia is currently facing its own "revusiran" moment with the nex-z clinical hold. However, bulls argue that a single death in a very sick patient population (ATTR amyloidosis) does not necessarily mean the CRISPR technology is flawed. If the HAELO trial for HAE (which is a different, younger patient group) succeeds mid-2026, the "platform risk" narrative will collapse, likely triggering a massive short squeeze.

A striking precedent thus exists. Alnylam Pharmaceuticals faced a devastating Phase 3 failure in 2016:

• 18 deaths

• Lead program scrapped

• Stock crushed into the low double digits

• Massive dilution fears

What happened next?

• Platform refined

• Multiple FDA approvals

• Stock later traded above $400

📌 Why this comparison matters (and where it doesn’t):

• ✔️ Shows platform science can survive catastrophic setbacks

• ❌ Does not guarantee NTLA repeats the story

Still — 1 death vs. 18 deaths is a material statistical difference (in NTLA's favor!).

🏦 Cash Runway: Longer Than the Market Thinks

• Cash (Q3 2025): ~$670M

• Burn: ~$95M/quarter

• Runway: into mid-to-late 2027

Plus:

• ATM facility already used strategically

• Partnership with Regeneron

• Optionality for non-dilutive financing

📌 Translation:
No gun to the head. No immediate forced dilution.

👉 Want the full picture? Dive into Intellia Therapeutics's financials here.

🧩 Institutional Signal: Goldman Steps In

Just when fear strikes a high note, a freshly filed Schedule 13G shows:

• Goldman Sachs owns ~5.1% of NTLA

• Shared voting & dispositive power

• Filed under Rule 13d-1(b)

Not activist. Not passive noise either.

Cathy Wood's funds also recently added [in moderation: NTLA only constitutes around 1.2% of ARK Innovation ETF (ARKK)'s portfolio and 2.28% of ARK Genomic Revolution ETF (ARKG)'s].

Just… interesting. 

🔍 For Intellia Therapeutics's Institutional Ownership breakdown, see here. 

🧠 FUNanc1al Take: This Is a Stress-Test Stock

Shorts are betting on extinction.
Insiders are betting on evolution.

If:

• FDA lifts the hold

• HAELO data delivers

• Platform risk narrative collapses

Then a violent repricing is plausible.

If not?
This thing can still go lower.

That’s biotech. No seatbelts.

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

✅ Quick Take / TL;DR

• NTLA is down ~55% on safety fears

• ~36% of the float is short

• Two directors bought ~$2.4M in stock 

• Cash runway extends into 2027

• Phase 3 HAELO data mid-2026 is decisive

• Asymmetric setup — not for the faint-hearted

❓ FAQ

Q: Is insider buying a guarantee?
No. It’s a signal — not a crystal ball. And the CEO is selling (10% of his holdings in 2 latest trades)

Q: Does the ALNY story mean NTLA will rebound?
No. It means rebounds can happen after biotech disasters.

Q: Could dilution still happen?
Yes — but timing matters, and NTLA isn’t forced today.

Q: Is this an investment or a trade?
For most: a speculative position, sized accordingly.

✍️ About the Author

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he blends sharp insights with humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he’s building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

We’re not doctors.
We’re not biotech regulators.
And this is not investment advice.

Biotech investing is inherently risky. Clinical trials fail. Stocks can go to zero.
🧠💊📉
With biotech investing, even your nerves are on trial.

We laugh, we analyze, we meme. 
We’re FUNancial advisors — not financial advisors. 😄📉📈
Consult a qualified financial professional if you must.

Invest at your own risk. Love at any pace. Laugh at every turn. 😄
Be Happy. 😄😄

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny